자가면역·염증성 · IL-17A

4개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs
AntibodyCurated CoreFDAUCBApproved

bimekizumab (Bimzelx, UCB4940, bimekizumab-bkzx)

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa · IL-17A / IL-17F

#IL-17AIL-17F#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 58Status Approved
AntibodyLimited DatastaleNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 148Status Active
AntibodyCurated CorestaleEli Lilly and CompanyApproved

Ixekizumab (Ixekizumab)

Psoriasis; Atopic Dermatitis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Approved#BioJungboMoa-pick#Popular+5
Trials 53Status Recruiting
AntibodyLimited DatastaleNovartis PharmaceuticalsPreclinical

Secikinumab (Secikinumab)

Axial Spondylarthritis (axSpA); Secukinumab · Psoriasis

#Psoriasis#Antibody#Preclinical#monoclonal-antibody#AxialSpondylarthritisaxSpA+2
Trials 2Status Active